> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Info on Postmarketing Adverse Drug Reporting Sent to OMB
- URL: https://www.fdaweb.com/info-on-postmarketing-adverse-drug-reporting-sent-to-omb/
- Published: 2016-02-03T12:00:00.000Z
- Updated: 2026-09-15T02:33:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5134654

*Federal Register* Notice: FDA’s collection of information entitled “Postmarketing Adverse Drug Experience Reporting” has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995\. To view this notice, click [here.](https://www.gpo.gov/fdsys/pkg/FR-2016-02-03/pdf/2016-01884.pdf?ref=fdaweb.com)